MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

29.98 1.94

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

29.51

Max

30.31

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-28M 22M
Pardavimai	4.3M 244M
P/E Sektoriaus vid.	10.72 63.808
Pelno marža	9.224
Darbuotojai	293
EBITDA	-22M 52M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+41.17% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	133M 1.7B
Ankstesnė atidarymo kaina	28.04
Ankstesnė uždarymo kaina	29.98

Naujienos nuotaikos

By Acuity

40%

60%

141 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-17 20:26; UTC

Įsigijimai, susijungimai, perėmimai

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

2026-04-17 18:15; UTC

Svarbiausios naujienos

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

2026-04-17 16:49; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

2026-04-17 16:49; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

2026-04-17 22:58; UTC

Uždarbis

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

2026-04-17 21:32; UTC

Rinkos pokalbiai

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

2026-04-17 21:22; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-17 21:22; UTC

Rinkos pokalbiai

Moody's Downgrades Belgium to A1 -- Market Talk

2026-04-17 20:52; UTC

Uždarbis

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

2026-04-17 20:50; UTC

Rinkos pokalbiai

Uždarbis

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-04-17 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-17 20:29; UTC

Uždarbis

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

2026-04-17 20:11; UTC

Įsigijimai, susijungimai, perėmimai

UCB to Buy Neurona Therapeutics for Up to $1.15B

2026-04-17 19:34; UTC

Rinkos pokalbiai

Uždarbis

Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2026-04-17 19:34; UTC

Rinkos pokalbiai

Uždarbis

Įsigijimai, susijungimai, perėmimai

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

2026-04-17 19:31; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

2026-04-17 19:26; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Edge Up -- Market Talk

2026-04-17 19:21; UTC

Rinkos pokalbiai

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

2026-04-17 19:15; UTC

Rinkos pokalbiai

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

2026-04-17 19:07; UTC

Rinkos pokalbiai

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

2026-04-17 18:57; UTC

Svarbiausios naujienos

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

2026-04-17 18:53; UTC

Įsigijimai, susijungimai, perėmimai

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

2026-04-17 18:53; UTC

Įsigijimai, susijungimai, perėmimai

UCB 2026 Rev Guidance Unchanged

2026-04-17 18:52; UTC

Įsigijimai, susijungimai, perėmimai

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

2026-04-17 18:52; UTC

Įsigijimai, susijungimai, perėmimai

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

2026-04-17 18:14; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

2026-04-17 18:00; UTC

Svarbiausios naujienos

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

2026-04-17 18:00; UTC

Svarbiausios naujienos

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

2026-04-17 17:31; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

2026-04-17 17:26; UTC

Rinkos pokalbiai

Uždarbis

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

41.17% į viršų

12 mėnesių prognozė

Vidutinis 41.25 USD 41.17%

Aukščiausias 62 USD

Žemiausias 25 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

141 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.